Redx Pharma pursues new reverse merger with Skye after 2023 setback
read at Endpoints ↗DealNeutral
Redx Pharma, a UK biotech focused on ROCK inhibitor therapies for fibrosis, is seeking a reverse merger with Skye to obtain a Nasdaq listing.
The company previously attempted a similar transaction in 2023, but that effort was cancelled.
By combining with Skye, Redx aims to tap public‑market capital and accelerate development of its pipeline.
The strategy reflects growing interest in reverse mergers as an alternative route to public financing for biotech firms.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Redx tries again at reverse merger, with Skye this time, as route gains steam”
read at Endpoints ↗88 words · retrieved Aug 14
comments(0)
5-min edit window · permanent after that